It is more than sad that we have a president whom lunatics look up to as a hero.
The Justice Department is opening a civil rights investigation into her death. But it’s fair to ask if it’s up to the task under Sessions.
Racist grandpas may be dying out, but their bigotry is regenerating in today’s youths.
The president has put my relationship with my own country on the rocks. Some days I think I don’t know it anymore.
His empathy for white grievance is nothing new.
Updating NAFTA makes sense, but using it to cut the trade gap through additional barriers and taxes on imports would hurt American workers and consumers.
The definition of “racism” has expanded to cover any expression that veers from left-wing dogma on race, making honest conversation impossible.
President Trump waited too long to denounce the hatred — but others spoke truth to power.
The incumbent president, who claimed victory, should refrain from quelling dissent with violence.
It is intolerable that Jamahri Sydnor’s life was taken and her dreams extinguished by a stray bullet on a D.C. street.
Defenders of monuments to the Confederate general are again trying to rewrite an ugly chapter in our nation’s history. If my family can move on, so can they.
A quiet wink at white supremacists followed by a belated condemnation fits the pattern he established in the campaign.
Trump likes to say that he’s strong on the military. But he’s weak. So weak.
There’s never been a golden age of free speech at American universities.
Comedy that appeals to young people can be surreal and dark — and completely meaningless.
They both hated, coddled and needed reporters.
When your boss can fire you for what you say, are you really free?
Polarization, technology and campus culture are all shifting rapidly. We need to keep up.
Maryland can’t imprison its way out of a drug epidemic.
But what’s frustrating to Arlington’s tree lovers is that such stories are unusual.
Too many elected officials are hit with fines — or worse — for violations.
The state’s cumbersome new law distracts from the more difficult and important challenge of lowering prices of patented brand-name drugs.
